You have 9 free searches left this month | for more free features.

Metastatic Refractory

Showing 1 - 25 of >10,000

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Pancreatic Cancer, Metastatic Pancreatic Cancer Trial in Tucson (Cabozantinib + Atezolizumab)

Recruiting
  • Pancreatic Cancer
  • Metastatic Pancreatic Cancer
  • Cabozantinib + Atezolizumab
  • Tucson, Arizona
    University of Arizona Cancer Center
Dec 14, 2022

Gastrointestinal Cancer Trial in Xuzhou (BGT007 Injection)

Recruiting
  • Gastrointestinal Cancer
  • BGT007 Injection
  • Xuzhou, JangSu, China
    he Affiliated Hospital of Xuzhou Medical University
Oct 23, 2023

NSCLC (NSCLC) Trial (Alirocumab and Cemiplimab)

Not yet recruiting
  • Non-small Cell Lung Cancer (NSCLC)
  • Alirocumab and Cemiplimab
  • (no location specified)
Jan 31, 2023

Digestive Tract Cancer Trial in Xuzhou (BGT007H Injection)

Recruiting
  • Digestive Tract Cancer
  • BGT007H Injection
  • Xuzhou, Jiangsu, China
    The Affiliated Hospital of Xuzhou Medical University
Oct 23, 2023

Refractory Metastatic Colorectal Cancer Trial in Berlin (Radiofrequency electromagnetic field treatment)

Recruiting
  • Refractory Metastatic Colorectal Cancer
  • Radiofrequency electromagnetic field treatment
  • Berlin, Germany
    Charité Universitätsmedizin Berlin
Aug 3, 2023

Metastatic Cancer, Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer Trial (OB-002)

Not yet recruiting
  • Metastatic Cancer
  • +5 more
  • (no location specified)
Jul 10, 2023

Anti-PD-1 Antibody Plus Regorafenib in Refractory Microsatellite

Completed
  • Metastatic Colorectal Adenocarcinoma
  • regorafenib plus anti-PD-1 antibodies
  • Changsha, Hunan, China
    Hunan Cancer hospital
Jul 4, 2023

NRAS/KRAS Mutated Advanced or Metastatic Refractory Solid Tumors Trial in Belgium, Netherlands, United Kingdom (LNP3794)

Active, not recruiting
  • NRAS/KRAS Mutated Advanced or Metastatic Refractory Solid Tumors
  • Brussels, Belgium
  • +3 more
Dec 24, 2021

Pancreatic Cancer Metastatic Trial (C3 (Metformin, Simvastatin, and Digoxin))

Not yet recruiting
  • Pancreatic Cancer Metastatic
  • C3 (Metformin, Simvastatin, and Digoxin)
  • (no location specified)
Sep 1, 2023

Fruquintinib Plus PD-1 in Refractory MSS Metastatic Colorectal

Completed
  • Colorectal Cancer
  • Fruquintinib combined with anti-PD-1 antibodies
  • ChangSha, Hunan, China
    Hunan Cancer Hospital
Aug 27, 2023

Trifluridine/Tipiracil Plus Bevacizumab Versus

Completed
  • Metastatic Colorectal Adenocarcinoma
  • Changsha, Hunan, China
    Hunan Cancer hospital
May 11, 2023

Metastatic Leiomyosarcoma, Metastatic Synovial Sarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma Trial in Seattle

Recruiting
  • Metastatic Leiomyosarcoma
  • +17 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Oct 13, 2022

Metastatic Pancreatic Cancer Trial (Azeliragon)

Not yet recruiting
  • Metastatic Pancreatic Cancer
  • (no location specified)
Mar 10, 2023

Refractory Soft Tissue Sarcomas Trial run by the NCI (Cabozantinib)

Active, not recruiting
  • Refractory Soft Tissue Sarcomas
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
Dec 5, 2022

Solid Tumor, Adult, Epithelial Ovarian Cancer, Small Cell Lung Carcinoma Trial in United States (CBX-12)

Recruiting
  • Solid Tumor, Adult
  • +11 more
  • New Haven, Connecticut
  • +3 more
May 9, 2022

Tumor Infiltrating Lymphocytes Trial (Autologous tumor-infiltrating lymphocytes)

Not yet recruiting
  • Tumor Infiltrating Lymphocytes
  • Autologous tumor-infiltrating lymphocytes
  • (no location specified)
Nov 28, 2021

Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma Trial in

Not yet recruiting
  • Clinical Stage III Cutaneous Melanoma AJCC v8
  • +4 more
  • Nashville, Tennessee
    Vanderbilt University/Ingram Cancer Center
Feb 28, 2023

Locally Advanced or Metastatic Radioiodine-Refractory

Recruiting
  • Thyroid Neoplasms
  • Anlotinib Hydrochloride Capsule
  • Beijing, Beijing, China
  • +2 more
Aug 9, 2023

Non Small Cell Lung Cancer, Metastatic NSCLC, Recurrent Non Small Cell Lung Cancer Trial (Pembrolizumab, GT103)

Not yet recruiting
  • Non Small Cell Lung Cancer
  • +2 more
  • (no location specified)
Jan 12, 2023

Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma

Recruiting
  • Anatomic Stage IV Breast Cancer AJCC v8
  • +20 more
  • Neoantigen Peptide Vaccine
  • +2 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Sep 7, 2022

Metastatic Colorectal Cancer Trial in Nanjing (Envafolimab, Trifluridine/Tipiracil, Bevacizumab)

Recruiting
  • Metastatic Colorectal Cancer
  • Nanjing, Jiangsu, China
    The First Affiliated Hospital with Nanjing Medical University
Sep 24, 2023

Triple Negative Breast Cancer Trial in Shanghai (Personalized treatment guided by mini-PDX and RNA sequencing, Nab paclitaxel,

Recruiting
  • Triple Negative Breast Cancer
  • Personalized treatment guided by mini-PDX and RNA sequencing
  • +5 more
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Apr 18, 2022

Hepatocellular Carcinoma, Hepatocellular Cancer, Metastatic Pancreatic Cancer Trial run by the NCI (nivolumab, tadalafil, oral

Completed
  • Hepatocellular Carcinoma
  • +4 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Feb 2, 2023

Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma

Not yet recruiting
  • Anatomic Stage III Breast Cancer AJCC v8
  • +4 more
  • Biopsy
  • +5 more
  • Buffalo, New York
    Roswell Park Cancer Institute
Feb 14, 2023

Locally Advanced or Metastatic Radioiodine-refractory Differentiated Thyroid Carcinoma Trial in Beijing (Anlotinib Hydrochloride

Not yet recruiting
  • Locally Advanced or Metastatic Radioiodine-refractory Differentiated Thyroid Carcinoma
  • Anlotinib Hydrochloride Capsule and Penpulimab
  • Beijing, Beijing, China
    YansongLin
Sep 25, 2023